Fennec's Pedmark meets in Phase III to prevent hearing loss associated with platinum-based chemotherapies

In October, Fennec Pharmaceuticals Inc. (TSX:FRX; NASDAQ:FENC) reported top-line data from the Phase III SIOPEL 6 trial in 99 children receiving platinum-based chemotherapies showing that Pedmark (STS, sodium thiosulfate) met the primary endpoint of reducing the incidence of cisplatin-induced hearing loss. Specifically, hearing loss occurred in 37% of patients receiving Pedmark plus cisplatin vs. 67% of patients receiving cisplatin alone (p=0.0033).

On secondary endpoints, the combo led to event-free survival at 3 years of 82.1% vs. 78.8% for cisplatin alone, and overall survival (OS) at 3 years of 98.2% vs. 92.3% for cisplatin alone. Pedmark was well tolerated. Data were presented at the International Society of Pediatric Oncology meeting in Washington...